www.analystratings.com/articles/...eives-a-buy-from-cowen-co/
May 12, 2019 Best Performing Analysts, Healthcare, Top Market News 0 Comments
Ovid Therapeutics Inc (OVID) Receives a Buy from Cowen & Co.
By Carrie Williams
[Ovid Therapeutics Inc (OVID) Receives a Buy from Cowen & Co.] In a report released yesterday, Ritu Baral from Cowen & Co. maintained a Buy rating on Ovid Therapeutics Inc (OVID Research Report). The companys shares closed on Friday at $1.71, close to its 52-week low of $1.64.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 27.3% and a 52.4% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.
Currently, the analyst consensus on Ovid Therapeutics Inc is a Strong Buy with an average price target of $13.40, implying a 683.6% upside from current levels. In a report issued on May 7, Ladenburg also maintained a Buy rating on the stock with a $27 price target.